Carol Torrington
Papers
2
Total Citations
346
H-Index
2
About
Carol Torrington is a leading urologic oncologist whose research has fundamentally reshaped the surgical management of bladder cancer. Her primary focus lies in comparing robot-assisted radical cystectomy (RARC) with the traditional open approach, particularly regarding patient recovery, surgical morbidity, and healthcare economics. Her landmark 2022 study, cited over 320 times, provided pivotal evidence on whether total intracorporeal surgery improves 90-day morbidity and mortality outcomes compared to open radical cystectomy—a question of immense clinical importance as robotic procedures gain popularity. Torrington’s work does not stop at clinical efficacy; she is equally renowned for her rigorous health policy analyses. Her 2023 cost-effectiveness study, with 26 citations, directly addressed the value proposition of robotic surgery for payers, clarifying whether the higher upfront costs of intracorporeal urinary diversion are justified by improved patient outcomes. By bridging surgical innovation with economic accountability, Torrington has become a trusted voice in evidence-based urologic practice. Her contributions empower surgeons and hospitals to make data-driven decisions, ensuring that technological advances translate into tangible benefits for patients and healthcare systems alike.
Research Focus
Key Achievements
Top Papers
- 1
- 2